Dr. Robert Rizza, M.D

NPI: 1942289947
Total Payments
$210,393
2021 Payments
$6,038
Companies
5
Transactions
96

Payment Breakdown by Category

Consulting$93,630 (44.5%)
Travel$73,618 (35.0%)
Research$33,698 (16.0%)
Other$6,600 (3.1%)
Food & Beverage$2,848 (1.4%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $93,630 18 44.5%
Travel and Lodging $73,618 54 35.0%
Unspecified $33,698 4 16.0%
Honoraria $6,600 1 3.1%
Food and Beverage $2,848 19 1.4%

Payments by Type

General
$176,695
92 transactions
Research
$33,698
4 transactions

Top Paying Companies

Company Total Records Latest Year
Novo Nordisk AS $110,600 38 $0 (2018)
Novo Nordisk Inc $49,701 38 $0 (2019)
Eli Lilly and Company $41,639 12 $0 (2021)
CSL Behring $7,203 7 $0 (2017)
Merck Sharp & Dohme Corporation $1,250 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2021 $6,038 1 Eli Lilly and Company ($6,038)
2020 $4,988 1 Eli Lilly and Company ($4,988)
2019 $35,158 21 Novo Nordisk Inc ($22,619)
2018 $92,988 30 Novo Nordisk AS ($75,018)
2017 $71,221 43 Novo Nordisk AS ($35,583)

All Payment Transactions

96 individual payment records from CMS Open Payments — Page 1 of 4

Date Company Product Nature Form Amount Type
09/27/2021 Eli Lilly and Company Consulting Fee Cash or cash equivalent $6,037.50 General
10/27/2020 Eli Lilly and Company Cash or cash equivalent $4,987.50 Research
12/05/2019 Novo Nordisk Inc Victoza (Drug) Consulting Fee Cash or cash equivalent $6,715.00 General
Category: Diabetes
12/05/2019 Novo Nordisk Inc Victoza (Drug) Travel and Lodging In-kind items and services $569.27 General
Category: Diabetes
12/05/2019 Novo Nordisk Inc Victoza (Drug) Travel and Lodging In-kind items and services $532.00 General
Category: Diabetes
12/05/2019 Novo Nordisk Inc Victoza (Drug) Travel and Lodging In-kind items and services $494.94 General
Category: Diabetes
12/05/2019 Novo Nordisk Inc Victoza (Drug) Travel and Lodging In-kind items and services $200.00 General
Category: Diabetes
12/05/2019 Novo Nordisk Inc Victoza (Drug) Travel and Lodging In-kind items and services $166.00 General
Category: Diabetes
11/03/2019 Eli Lilly and Company Travel and Lodging In-kind items and services $456.60 General
06/12/2019 Eli Lilly and Company Cash or cash equivalent $10,832.00 Research
06/06/2019 Novo Nordisk Inc Consulting Fee Cash or cash equivalent $2,890.00 General
06/06/2019 Novo Nordisk Inc Consulting Fee Cash or cash equivalent $2,890.00 General
06/06/2019 Novo Nordisk Inc Travel and Lodging In-kind items and services $600.00 General
06/06/2019 Novo Nordisk Inc Travel and Lodging In-kind items and services $255.27 General
06/06/2019 Novo Nordisk Inc Food and Beverage In-kind items and services $107.09 General
06/06/2019 Novo Nordisk Inc Food and Beverage In-kind items and services $79.55 General
05/22/2019 Novo Nordisk Inc Victoza (Drug) Consulting Fee Cash or cash equivalent $6,477.00 General
Category: Diabetes
05/22/2019 Novo Nordisk Inc Victoza (Drug) Travel and Lodging In-kind items and services $365.80 General
Category: Diabetes
05/22/2019 Novo Nordisk Inc Victoza (Drug) Travel and Lodging In-kind items and services $188.10 General
Category: Diabetes
05/22/2019 Novo Nordisk Inc Victoza (Drug) Travel and Lodging In-kind items and services $54.22 General
Category: Diabetes
05/22/2019 Novo Nordisk Inc Victoza (Drug) Travel and Lodging In-kind items and services $22.36 General
Category: Diabetes
05/22/2019 Novo Nordisk Inc Victoza (Drug) Food and Beverage In-kind items and services $12.72 General
Category: Diabetes
03/13/2019 Merck Sharp & Dohme Corporation Consulting Fee Cash or cash equivalent $1,250.00 General
11/13/2018 Eli Lilly and Company Cash or cash equivalent $8,953.00 Research
10/29/2018 Eli Lilly and Company Travel and Lodging In-kind items and services $443.48 General

About Dr. Robert Rizza, M.D

Dr. Robert Rizza, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942289947.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Rizza, M.D has received a total of $210,393 in payments from pharmaceutical and medical device companies, with $6,038 received in 2021. These payments were reported across 96 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($93,630).

Practice Information

  • Specialty Endocrinology, Diabetes & Metabolism
  • Other Specialties Diabetes & Metabolism
  • Location Rochester, MN
  • Active Since 01/10/2006
  • Last Updated 07/08/2007
  • Taxonomy Code 207RE0101X
  • Entity Type Individual
  • NPI Number 1942289947

Products in Payments

  • Victoza (Drug) $107,818
  • Product in Development (Biological) $7,203

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Endocrinology, Diabetes & Metabolism Doctors in Rochester